Abstract Library

#4043 Treatments, clinicopathological characteristics and prognosis in thymic neuroendocrine tumors (TNETs): With especial reference to Temozolomide (TMZ)-based chemotherapy

Introduction: Thymic neuroendocrine tumors (TNETs) are rare but aggressive malignant neoplasms that exhibit significant heterogeneity. However, there is a paucity of comprehensive clinical studies conducted to investigate the prognosis of TNETs.

Conference:

Presenting Author: Cheng Z

Authors: Cheng Z, Yu F, Cui L, Chen X, Zheng J,

Keywords: thymic neuroendocrine tumor, treatment, prognosis, temozolomide,

#3978 SDHx germline mutation in thymic neuroendocrine tumors

Introduction: Mutation in succinate dehydrogenase complex genes (SDHA, SDHB, SDHC, SDHD) could be found in 10% of hereditary paraganglioma-pheochromocytomas and gastrointestinal stromal tumors. Nearly 25% of thymic neuroendocrine tumors (TNETs) are asscociated with MEN1. TNETs asscociated with SDHx germline mutation have not been reported.

Conference:

Presenting Author: Liang Y

Authors: Liang Y, Chen J,

Keywords: SDHx，thymic neuroendocrine tumor,

#3454 Thymic neuroendocrine tumors: Case series from a Colombian hospital reference

Introduction: Thymic neuroendocrine tumors (tNET) are extremely rare, with a wide range of clinical manifestations, which can lead to underdiagnosis. Specific therapies have not been evaluated to improve survival.

Conference:

Presenting Author:

Authors: González Devia D, Fernández Mantilla D, Pino Villareal L, Segovia Gómez J, Urrego Meléndez O,

Keywords: Thymic Neuroendocrine Carcinoma, Thymic Neuroendocrine Tumor, Neuroendocrine Carcinoma, Cushing's Syndrome, Thymus,

#3341 A rare case of oligometastatic thymic carcinoid

Introduction: Primary thymic neuroendocrine tumors (NETs) are a rare type of cancer which have a propensity to local or distant spread to nodes, lung, and bone. Treatment consists of a combination of surgery, SACT and radiotherapy, depending on the stage.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Cooper J

Authors: Cooper J, Jethwa D, Zen Y, Prachalis A, Taylor B,

Keywords: thymic carcinoid, oligometastatic disease,

#2136 Combination of Capecitabine and Temozolomide for Advanced Thymic Neuroendocrine Tumors

Introduction: In vitro data indicate that the combination of capecitabine(CAP) and temozolomide(TEM) is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. It has been proven that the CAPTEM regimen is associated with an exceptionally high and durable response rate in patients with metastatic pancreatic neuroendocrine tumors. However, there is less evidence to illustrate if the CAPTEM regimen is effective for thymic neuroendorine tumors(TNET).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Tan H

Authors: Wang X, Li Y, Shi Y, Chen Y, Qiu X,

Keywords: thymic neuroendocrine tumors, capecitabine, temozolomide, progress-free survival, adverse effect,